SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

8 August 2008

 

 

PROTHERICS PLC

(Translation of Registrant’s Name Into English)

 

 

The Heath Business & Technical Park
Runcorn, Cheshire, W47 4QF England

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F       X              Form 40-F               

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):             

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 191(b)(7):             

 

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes                     No          X     

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-              .

 

 

The Registrant is furnishing a copy of its announcements as reported to the Company Announcements Office of the London Stock Exchange.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

       

 

PROTHERICS PLC

       

Date: 8 August 2008

 

By:

 

/s/ Rolf Soderstrom

       

Rolf Soderstrom

       

Finance Director

 

 

Protherics PLC


Notification of Major Interest in Shares



London, UK; Brentwood, TN, US; 8 August 2008 -  Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that the following notification of interest in the ordinary share capital of the Company was received today from Aviva plc.



1. Reason for the notification        (please tick the appropriate box or boxes)

 


An acquisition  voting rights 

√

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached



An event changing the breakdown of voting rights




Other (please specify): CHANGE TO THE TOTAL NUMBER OF VOTING RIGHTS IN ISSUE



2. Full name of person(s) subject to the notification obligation:

Aviva plc & its subsidiaries   

 

3. Full name of shareholder(s) (if different from 2.):

Registered Holder:


BNY Norwich Union Nominees Limited     
  6,741,190*


Chase GA Group Nominees Limited   17,297,355*


Chase Nominees Limited
979,009*    


CUIM Nominee Limited
5,150,906*


Vidacos Nominees Limited
70,303*


BNP Paribas - London
636,429


Chase Nominees Limited 
3,518,325


State Street Nominees Limited  
9,577,375


Vidacos Nominees Limited 
2,180,596    

*denotes direct interest  


4. Date of the transaction (and date on which the threshold is crossed or reached if different):

6 August 2008   

5. Date on which issuer notified:

8 August 2008   

6. Threshold(s) that is/are crossed or reached:

12% to 13% Change at Combined Interest level   


7. Notified details:






A: Voting rights attached to shares

Class/type of shares 

if possible using the ISIN CODE

Situation previous to the Triggering transaction 

Resulting situation after the triggering transaction

Number of Shares 

 Number of Voting Rights  

Number of shares 

Number of voting rights

% of voting rights

Direct

Direct  

Indirect 

Direct

Indirect

Ordinary Shares


GB0007029209

   


40,890,879


 

40,890,879

   


30,238,763

   


30,238,763

   


15,912,725

   


8.88%

   


4.68%





B: Financial Instruments

Resulting situation after the triggering transaction 

Type of financial instrument 

Expiration date 

Exercise/ Conversion Period/ Date  

Number of voting rights that may be   acquired if the instrument is exercised/ converted. 

% of voting rights


N/A



Total (A+B)

Number of voting rights

% of voting rights

   

46,151,488

   

13.56%





8. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable :

See Section 3




Proxy Voting:

9. Name of the proxy holder:

   See Section 3

10. Number of voting rights proxy holder will cease to hold:

   

11. Date on which proxy holder will cease to hold voting rights:

   




12. Additional information:

Figures are based on a total number of voting rights of 340,417,123






| Ends |



For further information please contact:


Protherics 


Nick Staples, Director of Corporate Affairs

+44 (0) 7919 480510  

Julie Vickers, Company Secretary 

+44 (0)1928 518010



Financial Dynamics  - press enquiries


London: Ben Atwell, Lara Mott

+44 (0) 20 7831 3113 

New York: John Capodanno

+1 212 850 5600




Or visit   www.protherics.com


Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Protherics Charts.
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Protherics Charts.